Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Public ClinicalTrials.gov record NCT04126317. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of action compared to intravitreal aflibercept injection (hereafter referred to as IAI).
Study identification
- NCT ID
- NCT04126317
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 106 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 4, 2019 (Actual)
- Primary completion
- May 14, 2021 (Actual)
- Completion
- Nov 30, 2021 (Actual)
- Last update posted
- Aug 14, 2023
2019 – 2021
United States locations
- U.S. sites
- 45
- U.S. states
- 24
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Study Site | Phoenix | Arizona | 85020 | — |
| Regeneron Study Site | Sun City | Arizona | 85351 | — |
| Regeneron Study Site | Encino | California | 91436 | — |
| Regeneron Study Site | Fullerton | California | 92835 | — |
| Regeneron Study Site | Mountain View | California | 94040 | — |
| Regeneron Study Site | Palm Desert | California | 92211 | — |
| Regeneron Study Site | Sacramento | California | 95819 | — |
| Regeneron Study Site | Santa Ana | California | 92705 | — |
| Regeneron Study Site | Colorado Springs | Colorado | 80909 | — |
| Regeneron Study Site | Golden | Colorado | 80401 | — |
| Regeneron Study Site | Waterford | Connecticut | 06385 | — |
| Regeneron Study Site | Fort Lauderdale | Florida | 33309 | — |
| Regeneron Study Site | Fort Myers | Florida | 33912 | — |
| Regeneron Study Site | Lakeland | Florida | 33805 | — |
| Regeneron Study Site | Largo | Florida | 33770 | — |
| Regeneron Study Site | Melbourne | Florida | 32901 | — |
| Regeneron Study Site | Tallahassee | Florida | 32308 | — |
| Regeneron Study Site | Winter Haven | Florida | 33880 | — |
| Regeneron Study Site | Augusta | Georgia | 30909 | — |
| Regeneron Study Site | Marietta | Georgia | 30060 | — |
| Regeneron Study Site | Oak Forest | Illinois | 60452 | — |
| Regeneron Study Site | Hagerstown | Maryland | 21740 | — |
| Regeneron Study Site | Royal Oak | Michigan | 48073 | — |
| Regeneron Study Site | Bloomfield | New Jersey | 07003 | — |
| Regeneron Study Site | Teaneck | New Jersey | 07666 | — |
| Regeneron Study Site | Albuquerque | New Mexico | 87102 | — |
| Regeneron Study Site | Great Neck | New York | 11021 | — |
| Regeneron Study Site | Asheville | North Carolina | 28803 | — |
| Regeneron Study Site | Charlotte | North Carolina | 28210 | — |
| Regeneron Study Site | Columbus | Ohio | 43212 | — |
| Regeneron Study Site | Edmond | Oklahoma | 73013 | — |
| Regeneron Study Site | Portland | Oregon | 97221 | — |
| Regeneron Study Site | Kingston | Pennsylvania | 18704 | — |
| Regeneron Study Site | Ladson | South Carolina | 29456 | — |
| Regeneron Study Site | West Columbia | South Carolina | 29169 | — |
| Regeneron Study Site | Rapid City | South Dakota | 57701 | — |
| Regeneron Study Site | Abilene | Texas | 79606 | — |
| Regeneron Study Site | Arlington | Texas | 76012 | — |
| Regeneron Study Site | Austin | Texas | 78705 | — |
| Regeneron Study Site | Houston | Texas | 77030 | — |
| Regeneron Study Site | The Woodlands | Texas | 77384 | — |
| Regeneron Study Site | Salt Lake City | Utah | 84107 | — |
| Regeneron Study Site | Fairfax | Virginia | 22031 | — |
| Regeneron Study Site | Spokane | Washington | 99204 | — |
| Regeneron Study Site | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04126317, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2023 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04126317 live on ClinicalTrials.gov.